<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653171</url>
  </required_header>
  <id_info>
    <org_study_id>12-221</org_study_id>
    <nct_id>NCT01653171</nct_id>
  </id_info>
  <brief_title>Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy</brief_title>
  <acronym>PRUE</acronym>
  <official_title>Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether premedication with Simethicone or
      Simethicone plus N-acetylcysteine are effective improving visibility during Upper endoscopy
      compared with use of water or no preparation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While globally there has been a downward trend in the incidence of gastric cancer, it remains
      the second leading cause of cancer mortality in the world. In Chile is the leading cause of
      death from malignant tumors in both sexes, and is recognized as a problem and public health
      priority in our country. Detection of gastric cancer in early stages has a huge impact on
      healing and therefore the prognosis of patients. In countries like Japan, where the incidence
      of this neoplasm is one of the highest in the world, mass screening programs have failed to
      demonstrate significant impact at the population level, there is a body of evidence to
      support endoscopic screening especially with the advent of new minimally invasive procedures
      such as endoscopic mucosal resection for gastric cancers detected in early stages. In our
      country, it is estimated that about half of the patients already have lymph node metastases
      or involvement of adjacent organs at diagnosis. The best way to reduce disease burden from
      this disease would be through primary prevention interventions or effective early detection.
      For this purpose the upper gastrointestinal endoscopy is the method of choice to examine the
      gastric mucosa in search of early lesions, and this is the point where adequate visibility of
      the mucosa is overriding. Mucus, foam and bubbles accumulated in the gastrointestinal tract
      mucosa interfere with adequate endoscopic visualization and thus represent risk of failing to
      diagnose early lesions. For this reason is that various anti-foam agents, anti-bubbles are
      widely used in endoscopic centers mainly in Japan, where its use is almost a rule, unlike the
      West where its use is limited by the theoretical risk of aspiration. Simethicone has been
      proven as a good anti-foam agent prior to endoscopy to remove mucus and bubbles. It has also
      been studied in other scenarios such as colonoscopy as an additive in the preparation of the
      colon to eliminate bubbles in endoscopic capsule for small bowel preparation as well as
      Endoscopic Ultrasound which reduces artifacts and increases the accuracy of the study.
      Currently N-acetylcysteine, a mucolytic agent, either alone or in combination with
      Simethicone has proven effective in removing mucus and gastric bubbles when used 20 minutes
      prior to the upper endoscopy, improving the visualization of the gastric mucosa. Other agents
      such as pronase have also been described as useful in this task are not yet available in our
      area. In the context of the relevance of gastric cancer in our environment, our low rate of
      early cancer detection and the absence of national policies on the preparation and agents
      that may improve visualization of the mucosa, this study aims to compare the effect of
      products available in our country in preparation for an endoscopy in order to improve
      visualization of the mucosa and increase the chance of recognizing early lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visibility at upper endoscopy</measure>
    <time_frame>During diagnostic upper endoscopy</time_frame>
    <description>The antrum, proximal part of the greater curvature, distal part of the greater curvature and the gastric fundus were assessed separately in terms of visibility mucosa. He scored from 1 to 4 each zone according to a score of visibility, as defined in previous publications by Chang et al. The sum of the scores from the four locations was defined as the total mucosal visibility score (TMVS) for each patient</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard upper endoscopy withouth premedication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mL of water, 20 minutes before upper endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simethicone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 500 mg + Simethicone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine 1000 mg + Simethicone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water (Placebo)</intervention_name>
    <description>Water 100 mL</description>
    <arm_group_label>Water</arm_group_label>
    <other_name>(Placebo)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simethicone</intervention_name>
    <description>200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination</description>
    <arm_group_label>Simethicone</arm_group_label>
    <arm_group_label>N-acetylcysteine 500 mg + Simethicone</arm_group_label>
    <arm_group_label>N-acetylcysteine 1000 mg + Simethicone</arm_group_label>
    <other_name>Flapex, Andromaco, Chile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine 500 mg</intervention_name>
    <description>500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination</description>
    <arm_group_label>N-acetylcysteine 500 mg + Simethicone</arm_group_label>
    <other_name>Mucolítico, Sanitas, Chile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine 1000 mg</intervention_name>
    <description>1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination</description>
    <arm_group_label>N-acetylcysteine 1000 mg + Simethicone</arm_group_label>
    <other_name>Mucolítico, Sanitas, Chile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic upper endoscopy performed for medical indications

        Exclusion Criteria:

          -  Upper gastrointestinal surgery

          -  Gastric Cancer

          -  Deep sedation with propofol

          -  Indication of therapeutic endoscopy

          -  Emergency endoscopy

          -  Patients with a history of

               -  Upper gastrointestinal bleeding

               -  Caustic ingestion

               -  Pregnancy

               -  Diabetes mellitus

               -  Asthma

               -  Allergic reactions to medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolfo Parra-Blanco, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esteban Glasinovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Monrroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Candia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>833-0024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, Ajiki W, Tsukuma H. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer. 2002 Feb 20;97(6):811-8.</citation>
    <PMID>11857360</PMID>
  </results_reference>
  <results_reference>
    <citation>Csendes A, Smok G, Medina E, Salgado I, Rivera R, Quitral M. [Clinical course characteristics of gastric cancer 1958-1990]. Rev Med Chil. 1992 Jan;120(1):36-42. Spanish.</citation>
    <PMID>1305308</PMID>
  </results_reference>
  <results_reference>
    <citation>McColl KE. Screening for early gastric cancer. Gut. 2005 Jun;54(6):740-2.</citation>
    <PMID>15888773</PMID>
  </results_reference>
  <results_reference>
    <citation>Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006 Aug 14;12(30):4873-4.</citation>
    <PMID>16937471</PMID>
  </results_reference>
  <results_reference>
    <citation>Everett SM, Axon AT. Early gastric cancer: disease or pseudo-disease? Lancet. 1998 May 2;351(9112):1350-2.</citation>
    <PMID>9643813</PMID>
  </results_reference>
  <results_reference>
    <citation>Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001 Feb;48(2):225-9.</citation>
    <PMID>11156645</PMID>
  </results_reference>
  <results_reference>
    <citation>Chávez Rossell M. [Endoscopic treatment of early gastric cancer: from Endoscopic Mucosal Resection (EMR) to Endoscopic Submucosal Dissection (ESD)]. Rev Gastroenterol Peru. 2005 Jan-Mar;25(1):76-92. Review. Spanish.</citation>
    <PMID>15818423</PMID>
  </results_reference>
  <results_reference>
    <citation>Fédération nationale des centres de lutte contre le cancer. [Recommendations for clinical practice: 2004 Standards, Options and Recommendations for management of patients with adenocarcinomas of the stomach (excluding cardial and other histological forms of cancer) Federation nationale des centres de lutte contre le cancer]. Gastroenterol Clin Biol. 2005 Jan;29(1):41-55. French.</citation>
    <PMID>15738894</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, Park DJ, Kim HH, Jung HC. Effect of endoscopic screening at 1-year intervals on the clinicopathologic characteristics and treatment of gastric cancer in South Korea. J Gastroenterol Hepatol. 2012 May;27(5):928-34. doi: 10.1111/j.1440-1746.2011.07038.x.</citation>
    <PMID>22142434</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhandari P, Green S, Hamanaka H, Nakajima T, Matsuda T, Saito Y, Oda I, Gotoda T. Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. Scand J Gastroenterol. 2010 Mar;45(3):357-61. doi: 10.3109/00365520903483643.</citation>
    <PMID>20148732</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonald GB, O'Leary R, Stratton C. Pre-endoscopic use of oral simethicone. Gastrointest Endosc. 1978 Nov;24(6):283.</citation>
    <PMID>365670</PMID>
  </results_reference>
  <results_reference>
    <citation>Banerjee B, Parker J, Waits W, Davis B. Effectiveness of preprocedure simethicone drink in improving visibility during esophagogastroduodenoscopy: a double-blind, randomized study. J Clin Gastroenterol. 1992 Oct;15(3):264-5.</citation>
    <PMID>1479177</PMID>
  </results_reference>
  <results_reference>
    <citation>McNally PR, Maydonovitch CL, Wong RK. The effectiveness of simethicone in improving visibility during colonoscopy: a double-blind randomized study. Gastrointest Endosc. 1988 May-Jun;34(3):255-8.</citation>
    <PMID>3292345</PMID>
  </results_reference>
  <results_reference>
    <citation>Tongprasert S, Sobhonslidsuk A, Rattanasiri S. Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol. 2009 Jun 28;15(24):3032-7.</citation>
    <PMID>19554657</PMID>
  </results_reference>
  <results_reference>
    <citation>Albert J, Göbel CM, Lesske J, Lotterer E, Nietsch H, Fleig WE. Simethicone for small bowel preparation for capsule endoscopy: a systematic, single-blinded, controlled study. Gastrointest Endosc. 2004 Apr;59(4):487-91.</citation>
    <PMID>15044883</PMID>
  </results_reference>
  <results_reference>
    <citation>Fang YH, Chen CX, Zhang BL. Effect of small bowel preparation with simethicone on capsule endoscopy. J Zhejiang Univ Sci B. 2009 Jan;10(1):46-51. doi: 10.1631/jzus.B0820148.</citation>
    <PMID>19198022</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang CC, Chen SH, Lin CP, Hsieh CR, Lou HY, Suk FM, Pan S, Wu MS, Chen JN, Chen YF. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol. 2007 Jan 21;13(3):444-7.</citation>
    <PMID>17230616</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuo CH, Sheu BS, Kao AW, Wu CH, Chuang CH. A defoaming agent should be used with pronase premedication to improve visibility in upper gastrointestinal endoscopy. Endoscopy. 2002 Jul;34(7):531-4.</citation>
    <PMID>12170403</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez del Río A, Alarcón Fernández O, Baudet JS, Sainz Menéndez Z, Socas Méndez M. Reliability of the Spanish version of a brief questionnaire on patient satisfaction with gastrointestinal endoscopy. Rev Esp Enferm Dig. 2005 Aug;97(8):554-61. English, Spanish.</citation>
    <PMID>16266222</PMID>
  </results_reference>
  <results_reference>
    <citation>Principles of training in gastrointestinal endoscopy. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 1999 Jun;49(6):845-53. Review.</citation>
    <PMID>10343249</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidad Catolica de Chile</investigator_affiliation>
    <investigator_full_name>Hugo Monrroy</investigator_full_name>
    <investigator_title>Internal Medicine Physician, Gastroenterology Residency Training Program</investigator_title>
  </responsible_party>
  <keyword>Acetylcysteine, Simethicone, Stomach Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

